Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer.


Journal

Scandinavian journal of urology
ISSN: 2168-1813
Titre abrégé: Scand J Urol
Pays: Sweden
ID NLM: 101587186

Informations de publication

Date de publication:
Feb 2022
Historique:
pubmed: 16 11 2021
medline: 9 2 2022
entrez: 15 11 2021
Statut: ppublish

Résumé

Bladder cancer is primarily a disease of older age and little is known about the differences between patients diagnosed with bladder cancer at a younger versus older age. Our objectives were to compare bladder cancer specific survival in patients aged <50 versus those aged 50-70 at time of diagnosis. The Swedish bladder cancer database provided data on patient demographics, clinical characteristics and treatments for this observational study. Cox proportional hazard regression models were adjusted for appropriate variables. All analyses were stratified by disease stage (non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. Furthermore, we compared the frequency of lower urinary tract infections within 24 months prior to bladder cancer diagnosis by sex and age groups. The study included 15,452 newly-diagnosed BC patients (1997-2014); 1,207 (8%) patients were <50 whilst 14,245 (92%) were aged 50-70. Patients aged <50 at diagnosis were at a decreased risk of bladder cancer death (HR = 0.82, 95%CI: 0.68-0.99) compared to those aged 50-70. When stratified by non-muscle-invasive and muscle-invasive bladder cancer, this association remained in non-muscle-invasive patients only (<50, HR = 0.43, 95% CI: 0.28-0.64). The frequency of lower urinary tract infection diagnoses did not differ between younger and older patients in either men or women. Patients diagnosed with non-muscle-invasive bladder cancer when aged <50 are at decreased risk of bladder cancer-specific death when compared to their older (50-70) counterparts. These observations raise relevant research questions about age-related differences in diagnostic procedures, clinical decision-making and, not least, potential differences in tumour biology.

Identifiants

pubmed: 34775873
doi: 10.1080/21681805.2021.2002399
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-33

Auteurs

Beth Russell (B)

Translational Oncology and Urology Research, King's College London, London, UK.

Fredrik Liedberg (F)

Department of Urology, Skåne University Hospital, Malmö, Sweden.
Institution of Translational Medicine, Lund University, Malmö, Sweden.

Oskar Hagberg (O)

Institution of Translational Medicine, Lund University, Malmö, Sweden.

Anders Ullén (A)

Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Stockholm, Sweden.
Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.

Karin Söderkvist (K)

Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.

Viveka Ströck (V)

Department of Urology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Firas Aljabery (F)

Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.

Truls Gårdmark (T)

Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.

Tomas Jerlström (T)

Department of Urology, Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.

Amir Sherif (A)

Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.

Lars Holmberg (L)

Translational Oncology and Urology Research, King's College London, London, UK.
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

Richard T Bryan (RT)

Bladder Cancer Research Centre, Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, UK.

Deborah Enting (D)

Department of Uro-Oncology, Guy's Hospital, Guy's St Thomas NHS Foundation Trust, London, United Kingdom.

Mieke Van Hemelrijck (M)

Translational Oncology and Urology Research, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH